DGIdb - LANREOTIDE Drug Record

LANREOTIDE chembl:CHEMBL1201185 ApprovedAntineoplastic

Alternate Names:

SOMATULINE AUTOGEL
LANREOTIDE
SOMATULINE LA
SOMATULINE
LANREOTIDE ACETATE
BIM 23014
DC 13-116
rxcui:68092
drugbank:06791
pubchem.compound:6918011
chemidplus:108736-35-2
chembl:CHEMBL1201185

Drug Info:

Year of Approval	2007
Drug Class	hormone replacement agents
FDA Approval	approved
Drug Class	Small molecule
Drug Indications	for treatment of acromegaly

(0 More Sources)

Publications:

Buil-Bruna et al., 2016, Population Pharmacokinetic Analysis of Lanreotide Autogel/Depot in the Treatment of Neuroendocrine Tumors: Pooled Analysis of Four Clinical Trials., Clin Pharmacokinet
Zatelli et al., 2005, Somatostatin analogs in vitro effects in a growth hormone-releasing hormone-secreting bronchial carcinoid., J. Clin. Endocrinol. Metab.
Huang et al., 2006, Lanreotide on collateral response to endothelin-1 and vasopressin in cirrhotic rats., J Chin Med Assoc

LANREOTIDE SSTR5

Interaction Score: 10.3

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name lanreotide,Somatuline Autogel, Somatuline Depot

Novel drug target Established target

PMIDs:
26416534 15671091

Sources:
TdgClinicalTrial NCI TEND
LANREOTIDE SSTR1

Interaction Score: 4.12

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name lanreotide ,Somatuline Autogel, Somatuline Depot

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial TEND
LANREOTIDE EDN1

Interaction Score: 3.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17051749

Sources:
NCI

TEND: LANREOTIDE
- Version: 01-August-2011
Alternate Names:

LANREOTIDE Primary Drug Name

Drug Info:

Drug Class hormone replacement agents

Year of Approval 2007

Publications:
TdgClinicalTrial: LANREOTIDE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications for treatment of acromegaly

Drug Class Small molecule

FDA Approval approved

Publications:

NCI: LANREOTIDE

Version: 14-September-2017

Alternate Names:

C1523 NCI drug code

Drug Info:

Publications:

Zatelli et al., 2005, Somatostatin analogs in vitro effects in a growth hormone-releasing hormone-secreting bronchial carcinoid., J. Clin. Endocrinol. Metab.

Huang et al., 2006, Lanreotide on collateral response to endothelin-1 and vasopressin in cirrhotic rats., J Chin Med Assoc

ChemblDrugs: chembl:CHEMBL1201185
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Trial Name	lanreotide,Somatuline Autogel, Somatuline Depot
Novel drug target	Established target

Trial Name	lanreotide ,Somatuline Autogel, Somatuline Depot
Novel drug target	Established target

LANREOTIDE Drug Record

LANREOTIDE chembl:CHEMBL1201185 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

LANREOTIDE SSTR5

Interaction Types & Directionality: agonist (activating)

Interaction Info: Trial Name lanreotide,Somatuline Autogel, Somatuline Depot Novel drug target Established target

PMIDs: 26416534 15671091

Sources: TdgClinicalTrial NCI TEND

LANREOTIDE SSTR1

Interaction Types & Directionality: n/a

Interaction Info: Trial Name lanreotide ,Somatuline Autogel, Somatuline Depot Novel drug target Established target

PMIDs: None found

Sources: TdgClinicalTrial TEND

LANREOTIDE EDN1

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17051749

Sources: NCI

TEND: LANREOTIDE

Alternate Names: LANREOTIDE Primary Drug Name

Drug Info: Drug Class hormone replacement agents Year of Approval 2007

Publications:

TdgClinicalTrial: LANREOTIDE

Alternate Names:

Drug Info: Drug Indications for treatment of acromegaly Drug Class Small molecule FDA Approval approved

Publications:

NCI: LANREOTIDE

Alternate Names: C1523 NCI drug code

Drug Info:

Publications: Zatelli et al., 2005, Somatostatin analogs in vitro effects in a growth hormone-releasing hormone-secreting bronchial carcinoid., J. Clin. Endocrinol. Metab. Huang et al., 2006, Lanreotide on collateral response to endothelin-1 and vasopressin in cirrhotic rats., J Chin Med Assoc

ChemblDrugs: chembl:CHEMBL1201185

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Trial Name lanreotide,Somatuline Autogel, Somatuline Depot

Novel drug target Established target

PMIDs:
26416534 15671091

Sources:
TdgClinicalTrial NCI TEND

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name lanreotide ,Somatuline Autogel, Somatuline Depot

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

n/a

PMIDs:
17051749

Sources:
NCI

Alternate Names:

LANREOTIDE Primary Drug Name

Drug Info:

Drug Class hormone replacement agents

Year of Approval 2007

Drug Info:

Drug Indications for treatment of acromegaly

Drug Class Small molecule

FDA Approval approved

Alternate Names:

C1523 NCI drug code

Publications:

Zatelli et al., 2005, Somatostatin analogs in vitro effects in a growth hormone-releasing hormone-secreting bronchial carcinoid., J. Clin. Endocrinol. Metab.

Huang et al., 2006, Lanreotide on collateral response to endothelin-1 and vasopressin in cirrhotic rats., J Chin Med Assoc